CeriBell, Inc. (NASDAQ:CBLL) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of CeriBell, Inc. (NASDAQ:CBLL) have earned an average rating of “Moderate Buy” from the seven brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $24.6667.

A number of equities research analysts recently commented on CBLL shares. TD Cowen reissued a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. BTIG Research reaffirmed a “buy” rating and issued a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. Finally, Canaccord Genuity Group raised their price objective on shares of CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th.

CeriBell Price Performance

CBLL stock traded down $0.74 during midday trading on Friday, hitting $17.66. 142,959 shares of the stock were exchanged, compared to its average volume of 331,271. The stock’s 50-day moving average price is $19.77 and its 200-day moving average price is $17.14. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.35 and a current ratio of 9.73. The stock has a market cap of $664.72 million, a price-to-earnings ratio of -12.01 and a beta of 1.12. CeriBell has a fifty-two week low of $10.01 and a fifty-two week high of $24.33.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.07. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%.The company had revenue of $24.78 million for the quarter, compared to analyst estimates of $23.95 million. Research analysts predict that CeriBell will post -2.46 earnings per share for the current year.

Insider Activity at CeriBell

In related news, CTO Raymond Woo sold 11,112 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $21.18, for a total transaction of $235,352.16. Following the sale, the chief technology officer owned 167,317 shares of the company’s stock, valued at $3,543,774.06. This trade represents a 6.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Josef Parvizi sold 25,000 shares of the business’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $22.94, for a total transaction of $573,500.00. Following the completion of the transaction, the director directly owned 747,652 shares of the company’s stock, valued at $17,151,136.88. The trade was a 3.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 203,627 shares of company stock valued at $4,156,660 in the last ninety days. 20.10% of the stock is owned by insiders.

Institutional Investors Weigh In On CeriBell

Hedge funds and other institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd lifted its stake in shares of CeriBell by 8,735.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,739 shares of the company’s stock valued at $60,000 after buying an additional 2,708 shares during the period. Invesco Ltd. grew its stake in CeriBell by 15.5% in the 4th quarter. Invesco Ltd. now owns 12,037 shares of the company’s stock worth $264,000 after acquiring an additional 1,618 shares during the period. Creek Drive Management Group LLC acquired a new position in CeriBell in the 4th quarter valued at $4,253,000. nVerses Capital LLC purchased a new position in shares of CeriBell during the 4th quarter worth $282,000. Finally, Tudor Investment Corp ET AL purchased a new position in shares of CeriBell during the 4th quarter worth $548,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.